PD-L1 (22C3)(FDA)

Identifies PD-L1 expression on tumor cells and tumor-associated immune cells. The 22C3 clone is FDA-approved as a companion diagnostic for selecting patients who may benefit from anti–PD-1/PD-L1 immunotherapies, including pembrolizumab. It is used across multiple tumor types, including non–small cell lung carcinoma, head and neck squamous cell carcinoma, gastric/GEJ adenocarcinoma, cervical cancer, and urothelial carcinoma.